Femta Pharmaceuticals and Lonza Group Ltd. Enter into Manufacturing Services Agreement and License for Lonza's GS Gene Expression System(TM)

SAN DIEGO & BASEL, Switzerland--(BUSINESS WIRE)--Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis. The agreement allows Femta access to Lonza’s GS Gene Expression System™ (GS: glutamine synthetase) along with cell line, purification and process development to support a robust cGMP process for Femta’s clinical development program.